Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score ® Test in Node-Negative Early Breast Cancer.
Vladislav BerdunovSteve MillenAndrew ParamoreJane GriffinSarah ReyniaNina FryerRebecca BrownLouise LongworthPublished in: ClinicoEconomics and outcomes research : CEOR (2022)
The analysis showed that the cost-effectiveness of the 21-gene assay is sensitive to assumptions for chemotherapy sparing for patients with RS 0-25 whose outcomes with endocrine therapy are no worse compared to chemotherapy-assigned patients, and a chemotherapy benefit in the RS 26-100 group. Future studies need to incorporate a wider set of tumour profiling tests other than the 21-gene assay to allow a direct comparison of their cost-effectiveness.
Keyphrases
- locally advanced
- end stage renal disease
- early breast cancer
- high throughput
- ejection fraction
- genome wide
- copy number
- chronic kidney disease
- newly diagnosed
- squamous cell carcinoma
- peritoneal dialysis
- single cell
- genome wide identification
- chemotherapy induced
- type diabetes
- current status
- gene expression
- radiation therapy
- patient reported outcomes
- free survival
- bone marrow
- metabolic syndrome
- transcription factor
- glycemic control
- genome wide analysis
- patient reported
- data analysis